<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03378479</url>
  </required_header>
  <id_info>
    <org_study_id>POSA-FLU</org_study_id>
    <nct_id>NCT03378479</nct_id>
  </id_info>
  <brief_title>Posaconazole for the Prevention of Influenza-associated Aspergillosis in Critically Ill Patients</brief_title>
  <acronym>POSA-FLU</acronym>
  <official_title>A Phase iv, Interventional, Non-blinded, Randomized Controlled Multicenter Study of Posaconazole Prophylaxis for the Prevention of Influenza-associated Aspergillosis (IAA) in Critically Ill Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Universitaire Ziekenhuizen Leuven</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Universitaire Ziekenhuizen Leuven</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to deliver proof of concept that antifungal prophylaxis can&#xD;
      reduce the incidence of Influenza Associated Aspergillosis (IAA) in ICU (intensive care unit)&#xD;
      patients with severe influenza.&#xD;
&#xD;
      The investigators will perform an interventional non-blinded randomized controlled&#xD;
      multicentric proof-of-concept study in patients with severe influenza admitted to the ICU.&#xD;
      Patients will be randomized to the posaconazole prophylaxis group or to the SOC (standard of&#xD;
      care) group. Oseltamivir will be started at the discretion of the investigator. Patients in&#xD;
      the posaconazole group will receive posaconazole prophylaxis for 7 days.&#xD;
&#xD;
      addendum: pharmacokinetics of posaconazole as prophylaxis for invasive fungal disease on ICU&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Critically ill patients with PCR-confirmed influenza criteria) are eligible for inclusion in&#xD;
      this study and will be randomized to or the posaconazole prophylaxis group or the SOC group.&#xD;
&#xD;
      If a patient is randomized to the posaconazole prophylaxis group, posaconazole (Noxafil, MSD)&#xD;
      will be started intravenously from day 1 of randomization (2*300mg( milligram) /d on day 1,&#xD;
      followed by 1*300mg/d from day 2 for 7 days) In both patient groups (prophylaxis and SOC)&#xD;
      oseltamivir (non-IMP) will be started at the discretion of the treating physician from the&#xD;
      first day of ICU admission as 2*150 mg/day for 10 days. If oseltamivir had already been&#xD;
      started up before ICU admission, oseltamivir treatment will be continued up to a total of 10&#xD;
      days.&#xD;
&#xD;
      Within 48 hours after influenza diagnosis a bronchoscopy with BAL (bronchoalveolar lavage)&#xD;
      and a serum galactomannan will be performed as part of routine ICU care in this type of&#xD;
      patients. If an IAA-infection is suspected based on the result of this BAL ((A) Aspergillus&#xD;
      cultured from BAL, or (B) a galactomannan (GM)the patient will be withdrawn from the study&#xD;
      and antifungal treatment will be started.&#xD;
&#xD;
      addendum: Extensive PK sampling (UZ Leuven and Radboud): full PK curve on day 2 and day 5&#xD;
      (predose, 1.5; 2,3,4,6,8,10,12,18,24 h post infusion).&#xD;
&#xD;
      on non PK days, until day 7, predose sample. PK in BAL fluid only in patients with mechanical&#xD;
      ventilation and when medically indicated.&#xD;
&#xD;
      Limited PK sampling: on day 2 and day 5: 1.5-3h, 4-8 h;8-12h; 12-24h post dose. on non PK&#xD;
      days: PK pre dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Based on interim analysis of results&#xD;
  </why_stopped>
  <start_date type="Actual">December 27, 2017</start_date>
  <completion_date type="Actual">June 30, 2020</completion_date>
  <primary_completion_date type="Actual">March 31, 2020</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The incidence of IAA-infection at ICU discharge</measure>
    <time_frame>from date of admission in ICU assessed up to ICU discharge, approximately 21 days</time_frame>
    <description>A patient with IAA-infection is defined as a patient having mycological evidence of Aspergillus and at least one Aspergillus compatible sign or symptom and radiological abnormalities</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Time to IAA diagnosis</measure>
    <time_frame>from date of inclusion to date of first sign/symptom of IAA infection, assessed up to ICU discharge, approximately 10 days</time_frame>
    <description>days to IAA diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of ICU stay</measure>
    <time_frame>from date of admission in ICU to date of discharge from ICU, approximately 20 days</time_frame>
    <description>amount of days at ICU</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>length of hospital stay</measure>
    <time_frame>from date of admission in hospital to date of discharge from hospital, approximately 25 days</time_frame>
    <description>admission days</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>mortality</measure>
    <time_frame>at day 30 and at day 90</time_frame>
    <description>survival status</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>identify changes in PK of posaconazole in critically ill patients</measure>
    <time_frame>from day 1 until day 7</time_frame>
    <description>altered clearance of posaconazole in critically ill patients</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">88</enrollment>
  <condition>Aspergillosis; Pulmonary, Invasive (Etiology)</condition>
  <arm_group>
    <arm_group_label>SOC + 'Posaconazole 18 MG/ML'</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care (SOC) treatment for influenza pneumonia +posaconazole 2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days; vials containing 18mg posaconazole /mL, 300mg posaconazole/vial in total)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Standard of Care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>standard of care treatment for influenza pneumonia (at the investigators discretion)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>SOC +Posaconazole 18 MG/ML (milligram/milliliter)</intervention_name>
    <description>.2*300mg/d IV on day 1, followed by 1*300mg/d IV from day 2 for 7 days (total 7 days)</description>
    <arm_group_label>SOC + 'Posaconazole 18 MG/ML'</arm_group_label>
    <other_name>Noxafil</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>standard of care (SOC)</intervention_name>
    <description>treatment for influenza pneumonia at the investigators discretion</description>
    <arm_group_label>SOC + 'Posaconazole 18 MG/ML'</arm_group_label>
    <arm_group_label>Standard of Care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written informed consent must be obtained from the patient or his/her legal&#xD;
             representative prior to any study procedures&#xD;
&#xD;
          2. Adult patient (≥ 18 years)&#xD;
&#xD;
          3. PCR-confirmed influenza based on nasopharyngeal swab (NS), bronchial aspirate (BA) or&#xD;
             broncho-alveolar lavage (BAL) within 7 days before ICU admission or within 48 hours&#xD;
             after ICU admission. If PCR is not available a positive result of a rapid test is&#xD;
             required (a negative rapid test does not imply absence of influenza and thus requires&#xD;
             confirmation by PCR)&#xD;
&#xD;
          4. Influenza symptoms present for no more than 10 days before ICU admission&#xD;
&#xD;
          5. Respiratory distress as the main reason for ICU admission. Respiratory distress will&#xD;
             be defined as tachypnea with an respiratory rate ≥ 25x/min and a paO2/fiO2-ratio&#xD;
             (fraction of inspired oxygen) ≤ 300 with or without (bilateral) infiltrates.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients with age &lt; 18 years&#xD;
&#xD;
          2. Pregnant women (based on a positive serum sample)&#xD;
&#xD;
          3. Expected survival on ICU admission ≤ 48h&#xD;
&#xD;
          4. Patients having influenza symptoms for more than 10 days before ICU admission&#xD;
&#xD;
          5. Patients being transferred from another hospital ward or another hospital who already&#xD;
             have mycological evidence for an IAA-infection (based on sputum, BA or BAL culture,&#xD;
             BAL or serum GM)&#xD;
&#xD;
          6. Patients with known intolerance or hypersensitivity to posaconazole or other azole&#xD;
             antifungal agents&#xD;
&#xD;
          7. Patients that are being treated actively with antifungal agents for invasive&#xD;
             aspergillosis&#xD;
&#xD;
          8. Patients with a QTc (corrected QT interval) interval ≥500 msec&#xD;
&#xD;
          9. Patients with liver cirrhosis (Child C)&#xD;
&#xD;
         10. Participation in another interventional clinical trial -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joost Wauters, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>UZ Leuven</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Paul Verweij, Phd</last_name>
    <role>Principal Investigator</role>
    <affiliation>Radboud UMC</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>AZ Sint Jan</name>
      <address>
        <city>Brugge</city>
        <zip>8000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Gent</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UZ Leuven</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>AZ Delta</name>
      <address>
        <city>Roeselare</city>
        <zip>8800</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitair Medisch Centrum</name>
      <address>
        <city>Groningen</city>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UMC Radboud</name>
      <address>
        <city>Nijmegen</city>
        <zip>6500</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MC Erasmus</name>
      <address>
        <city>Rotterdam</city>
        <zip>3015</zip>
        <country>Netherlands</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Netherlands</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 30, 2017</study_first_submitted>
  <study_first_submitted_qc>December 18, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 19, 2017</study_first_posted>
  <last_update_submitted>April 20, 2021</last_update_submitted>
  <last_update_submitted_qc>April 20, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 23, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Universitaire Ziekenhuizen Leuven</investigator_affiliation>
    <investigator_full_name>Joost Wauters, prof. dr.</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Influenza</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Influenza, Human</mesh_term>
    <mesh_term>Aspergillosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Posaconazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

